IL-32γ inhibits cancer cell growth through inactivation of NF-B and STAT3 signals

Oncogene

Volumn 30, Issue 30, 2011, Pages 3345-3359

  Oh, J H ^a   Cho, M C ^a   Kim, J H ^b   Lee, S Y ^a   Kim, H J ^b   Park, E S ^a   Ban, J O ^a   Kang, J W ^b   Lee, D H ^b   Shim, J H ^b   Han, S B ^a   Moon, D C ^a   Park, Y H ^c   Yu, D Y ^c   Kim, J M ^d   Kim, S H ^b   Yoon, D Y ^b   Hong, J T ^a  

^a Chungbuk National University   (South Korea)

^b Konkuk University   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^d Chungnam National University   (South Korea)

Author keywords

colon cancer; cytokine; IL 32; NF B; STAT3

Indexed keywords

CASPASE 3; CASPASE 9; CYCLIN D; CYCLIN DEPENDENT KINASE 4; CYCLOOXYGENASE 2; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INHIBITOR OF APOPTOSIS PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 32; INTERLEUKIN 32GAMMA; INTERLEUKIN 6; PROTEIN BAX; PROTEIN BCL 2; SMALL INTERFERING RNA; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CD8+ T LYMPHOCYTE; COLON CANCER; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; CYTOKINES; GENE SILENCING; HCT116 CELLS; HUMANS; INTERLEUKINS; KILLER CELLS, NATURAL; MALE; MELANOMA; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NF-KAPPA B; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

MUS MUSCULUS;

EID: 79960838180     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.52     Document Type: Article

References (54)

1. Araki S, Omorin Y, Lyn D, Singh RK, Meinbach DM, Sandman Y et al. (2007). Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res 67: 6854-6862. (Pubitemid 47105532)
2. Ban JO, Oh JH, Hwang BY, Moon DC, Jeong HS, Lee S et al. (2009). Inflexinol inhibits colon cancer cell growth through inhibition of nuclear factor-kappaB activity via direct interaction with p50. Mol Cancer Ther 8: 1613-1624.
3. Baud V, Karin M. (2009). Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8: 33-40.
4. Bollrath J, Greten FR. (2009). IKK/NF-kappaB and STAT3 pathways: central signaling hubs in inflammation-mediated tumor promotion and metastasis. EMBO Rep 10: 1314-1319.
5. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C et al. (1999). Stat3 as an oncogene. Cell 98: 295-303. (Pubitemid 29380565)
6. Cacev T, Radosevic S, Krizanac S, Kapitanovic S. (2008). Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression. Carcinogenesis 29: 1572-1580.
7. Calabrese F, Baraldo S, Bazzan E, Lunardi F, Rea F, Maestrelli P et al. (2008). IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 178: 894-901.
8. Chan KS, Sano S, Kiguchi K, Anders J, Komazawa N, Takeda J et al. (2004). Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest 114: 720-728. (Pubitemid 39578762)
9. Choi JD, Bae SY, Hong JW, Azam T, Dinarello CA, Her E et al. (2009). Identification of the most active interleukin-32 isoform. Immunology 126: 535-542.
10. Choi J, Bae S, Hong J, Ryoo S, Jhun H, Hong K et al. (2010). Paradoxical effects of constitutive human IL-32gamma in transgenic mice during experimental colitis. Proc Natl Acad Sci USA 107: 21082-21086.
11. Choi KC, Jung MG, Lee YH, Yoon JC, Kwon SH, Knag HB et al. (2002). Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation. Cancer Res 69: 583-592.
12. Dahl CA, Schall RP, He HL, Cairns JS. (1992). Identification of a novel gene expressed in activated natural killer cells and T cells. J Immunol 148: 597-603.
13. Dinarello CA, Kim SH. (2006). A novel cytokine with a possible role in disease. Ann Rheum Dis 65: iii61-iii64. (Pubitemid 44629106)
14. Fujimoto J, Aoki I, Toyoki H, Khatun S, Tamaya T. (2002). Clinical implications of expression of ETS-1 related to angiogenesis in uterine cervical cancer. Ann Oncol 13: 1598-1604. (Pubitemid 35331457)
15. Goda C, Kanaji T, Kanaji S, Tanaka G, Arima K, Ohno S et al. (2006). Involvement of IL-32 in activation-induced cell death in T cells. Int Immunol 18: 233-240. (Pubitemid 43160136)
16. Grivennikov SI, Karin M. (2010). STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 21: 11-19.
17. Groscurth P, Diener S, Stahel R, Jost L, Kagi D, Hengartner H. (1990). Morphologic analysis of human lymphokine-activated killer (LAK) cells. Int J Cancer 45: 694-704. (Pubitemid 20146132)
18. Hardwick JC, van den Brink GR, Offerhaus GJ, van Deventer SJ, Peppelenbosch MP. (2001). NF-kappaB, p38 MAPK and JNK are highly expressed and active in the stroma of human colonic adenomatous polyps. Oncogene 20: 819-827. (Pubitemid 32198175)
19. Hisada M, Kamiya S, Fujita K, Belladonna ML, Aoki T, Koyanagi Y et al. (2004). Potent antitumor activity of interleukin-27. Cancer Res 64: 1152-1156. (Pubitemid 38176923)
20. Hou T, Ray S, Lee C, Brasier AR. (2008). The STAT3 NH2-terminal domain stabilizes enhanceosome assembly by interacting with the p300 bromodomain. J Biol Chem 283: 30725-30734.
21. Huang S, Xie K, Bucana CD, Ullrich SE, Bar-Eli M. (1996). Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin Cancer Res 2: 1969-1979. (Pubitemid 27006629)
22. Jee SH, Shen SC, Chiu HC, Tsai WL, Kuo ML. (2001). Over-expression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency. Oncogene 20: 198-208.
23. Jenkins BJ, Roberts AW, Najdovska M, Grail D, Ernst M. (2005). The threshold of 130-dependent STAT3 signaling is critical for normal regulation of hematopoiesis. Blood 105: 3512-3520. (Pubitemid 40628193)
24. Kang JW, Choi SC, Cho MC, Kim HJ, Kim JH, Lim JS et al. (2009). A proinflammatory cytokine interleukin-32b promotes the production of an anti-inflammatory cytokine interleukin-10. Immunology 128: e532-e540.
25. Karin M, Cao Y, Greten FR, Li ZW. (2002). NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2: 301-310. (Pubitemid 37328783)
26. Kim KH, Shim JH, Seo EH, Cho MC, Kang JW, Kim SH et al. (2008). Interleukin-32 monoclonal antibodies for immunohistochemistry, Western blotting, and ELISA. J Immunol Methods 333: 38-50.
27. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. (2005). IL-32: a cytokine and inducer of TNFalpha. Immunity 22: 131-142.
28. Kundu N, Fulton AM. (1997). Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis. Cell Immunol 180: 55-61. (Pubitemid 27433618)
29. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z et al. (2009). Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer cell 15: 283-293.
30. Lee J, Fenton BM, Koch CJ, Frelinger JG, Lord EM. (1998). Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment. Cancer Res 58: 1478-1485. (Pubitemid 28193611)
31. Lee S, Kim S, Bae S, Choi J, Hong J, Ryoo S et al. (2010). Interleukin-32 gamma specific monoclonal antibody and developing IL-32 specific ELISA. Hybridoma 29: 501-509.
32. Levy DE, Darnell Jr JE. (2002). Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651-662. (Pubitemid 34987786)
33. Lin WW, Karin M. (2007). A cytokine-mediated link between innate immunity, inflammation and cancer. J Clin Invest 117: 1175-1183.
34. Lind DS, Hochwald SN, Malaty J, Rekkas S, Hebig P, Mishra G et al. (2001). Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery 130: 363-369. (Pubitemid 32721692)
35. Lu C, Soria JC, Tang X, Xu XC, Wang L, Mao L et al. (2004). Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol 22: 4575-4583. (Pubitemid 41185125)
36. Ma X, Reynolds SL, Baker BJ, Li X, Benveniste EN, Qin H. (2010). IL-17 enhancement of the IL-6 signaling cascade in astrocytes. J Immunol 184: 4898-4906.
37. Mantovani A, Allavena P, Sica A, Balkwill F. (2008). Cancer-related inflammation. Nature 454: 436-444.
38. Marcondes AM, Mhyre AJ, Stirewalt DL, Kim SH, Dinarello CA, Deeg HJ. (2008). Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc Natl Acad Sci USA 105: 2865-2870. (Pubitemid 351723635)
39. Moretta L, Biassoni R, Bottino C, Mingari MC, Moretta A. (2000). Human NK-cell receptors. Immunol Today 21: 420-422.
40. Naugler WE, Karin M. (2008). NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 18: 19-26.
41. Nishida A, Andoh A, Inatomi O, Fujiyama Y. (2009). Interleukin-32 expression in the pancreas. J Biol Chem 284: 17868-17876.
42. Nold-Petry CA, Nold MF, Zepp JA, Kim SH, Voelkel NF, Dinarello CA. (2009). IL-32-dependent effects of IL-1beta on endothelial cell functions. Proc Natl Acad Sci USA 106: 3883-3888.
43. Ray S, Lee C, Hou T, Boldogh I, Brasier AR. (2008). Requirement of histone deacetylase1 (HDAC1) in signal transducer and activator of transcription 3 (STAT3) nucleocytoplasmic distribution. Nucleic Acids Res 36: 4510-4520.
44. Schottelius AJ, Mayo MW, Sartor RB, Baldwin Jr AS. (1999). Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 274: 31868-31874.
45. Seo EH, Kang J, Kim KH, Cho MC, Lee S, Kim HJ et al. (2008). Detection of expressed IL-32 in human stomach cancer using ELISA and immunostaining. J Microbiol Biotechnol 18: 1606-1612.
46. Shurin MR, Shurin GV, Lokshin A, Yurkovetsky ZR, Gutkin DW, Chatta G et al. (2006). Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metast Rev 25: 333-356. (Pubitemid 44922354)
47. Son DJ, Park MH, Chae SJ, Moon SO, Lee JW, Song HS et al. (2007). Inhibitory effect of snake venom toxin from Vipera lebetina turanica on hormone-refractory human prostate cancer cell growth: induction of apoptosis through inactivation of nuclear factor kappaB. Mol Cancer Ther 6: 675-683. (Pubitemid 46332468)
48. Sorrentino C, Di Carlo E. (2009). Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. Am J Respir Crit Care Med 180: 769-779.
49. Yu H, Pardoll D, Jove R. (2009). STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9: 798-809.
50. Wang AG, Moon HB, Lee MR, Hwang CY, Kwon KS, Yu SL et al. (2005). Gender-dependent hepatic alterations in H-ras 12V transgenic mice. J Hepatol 43: 836-844. (Pubitemid 41414510)
51. Wang L, Walia B, Evans J, Gewirtz AT, Merlin D, Sitaraman SV. (2003). IL-6 induces NF-kappa B activation in the intestinal epithelia. J Immunol 171: 3194-3201. (Pubitemid 37093545)
52. Westbrook AM, Wei B, Braun J, Schiestl RH. (2009). Intestinal mucosal inflammation leads to systemic genotoxicity in mice. Cancer Res 69: 4827-4834.
53. Zhang F, Suares G, Sha J, Sierra JC, Peterson JW, Chopra AK. (2009). Phospholipase A2-activating protein (PLAA) enhances cisplatin-induced apoptosis in HeLa cells. Cell signal 21: 1085-1099.
54. Zheng LM, Ojcius DM, Garaud F, Roth C, Maxwell E, Li Z et al. (1996). Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 184: 579-584. (Pubitemid 26324111)